Fiche centre
Research Site
Shijiazhuang — China
Essais liés4clinical trials
VilleShijiazhuanglocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06455449
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Anifrolumab (blinded) | Myopathies | Phase 3 | NCT06455449 | JASMINE — A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05138133 | IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Ravulizumab | Myasthénie | Phase 3 | NCT07596784 | Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT07751848 | LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | RECRUITING |